Palbociclib 100mg

DRUG3 trials

Sponsors

Pfizer, Canadian Cancer Trials Group, University of Kansas Medical Center

Conditions

Breast CancerBreast Cancer MetastaticHER2-positive Breast CancerHealthy

Phase 1

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

CompletedNCT02059330

Start: 2014-03-31End: 2014-06-30Updated: 2014-06-24

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

TerminatedNCT03709082

University of Kansas Medical CenterBreast Cancer Metastatic, HER2-positive Breast Cancer

Start: 2018-10-15End: 2021-02-03Updated: 2024-03-05

Phase 2

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

CompletedNCT02630693

Canadian Cancer Trials GroupBreast Cancer

Start: 2016-04-08End: 2023-11-29Updated: 2025-11-25

Related Papers

Abstract P5-02-27: Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial

Cancer Research2023-03-01

Abstract P5-13-10: Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

Cancer Research2022-02-15

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

Cancer Research2019-02-158 citations

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Cancer Science2016-03-1989 citations